TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00893451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (TillVal-D)
Description: In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice daily
Study: NCT02124902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT01923857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg
Study: NCT01665417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Icotinib: 125mg, oral administration, three times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Study: NCT01370278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
Study: NCT02124902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01370278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
Study: NCT01668563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical management
Description: Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular management
Description: Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
Study: NCT02004756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
Study: NCT03988829

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-C
Description: This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-C
Description: In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-C+
Description: A commercial video game will be used that requires a lot of demand on attentional control.
Study: NCT02385825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
Study: NCT02385825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
Study: NCT02124902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET/MR
Description: * Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study
Study: NCT00571363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard surgery
Description: excision with 4 mm margins

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mohs micrographic surgery
Description: excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
Study: NCT04374825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Stress Management (CBSM)
Description: This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
Study: NCT03434197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esflurbiprofen
Description: A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac diethylamine
Description: A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
Study: NCT02589405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermotivin® Soft Liquid cleanser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil® Dermacontrol Moisturizer SPF30
Study: NCT04467320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques
Description: Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
Study: NCT00003317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study: NCT02905149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serrato
Description: Serratus plane block.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard anesthesia
Study: NCT03812120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural closure with L-PRF
Description: Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dural closure with classical fibrin sealants
Description: Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
Study: NCT00169754

Intervention type: OTHER
Group type: OTHER
Intervention: mapping kidney anatomy
Description: videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
Study: NCT03540212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir and sofosbuvir
Description: Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.
Study: NCT03301701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Radical prostatectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR (19Gy) or SBRT (35-40Gy)
Description: Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
Study: NCT03821909

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound-guided protal venous blood sampling
Description: We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound-guided protal venous blood sampling
Description: We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
Study: NCT03330288

Intervention type: DRUG
Intervention: Theraflex, BAY 874017
Description: The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day

Intervention type: DRUG
Intervention: Theraflex, BAY 874017
Description: The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
Study: NCT00203073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg
Description: glatiramer acetate 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg, with mitoxantrone
Description: glatiramer acetate 20 mg, with mitoxantrone
Study: NCT01173354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free balanced amino acid mixture
Description: 7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Free essential amino acid mixture
Description: 7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
Study: NCT04633577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.9% normal saline
Study: NCT02653183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: Aquacel Surgical
Description: Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Mepilex Border Post-Op
Description: Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days.
Study: NCT01719783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV H5N2
Description: 2 doses provided intranasally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo provided intranasally
Study: NCT00885053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
Study: NCT02676115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Post Operative Skin Care
Description: Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
Study: NCT01923857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg
Study: NCT01385865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract
Description: 18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
Study: NCT05939557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jones technique
Description: is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jones technique
Description: is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
Study: NCT04381494

Intervention type: DEVICE
Group type: OTHER
Intervention: Multiparametric Mobile Technology
Description: Using a spirometer, an armband, and a tablet to collect data.
Study: NCT00465751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chenodeoxycholic acid
Description: chenodeoxycholic acid 500 mg capsules tid po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: placebo capsules containing mannitol tid po
Study: NCT00003317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT04172324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIBBOT
Description: Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
Study: NCT01760291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN LAA Closure Technology
Study: NCT04315454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
Study: NCT04172324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care involves the standard physiotherapy the child would get during clinical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care involves the standard physiotherapy the child would get during clinical care.
Study: NCT01802229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh placement
Description: Placement of a Omega 3 mesh, fixed to the border of the fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial suture
Description: The port-site hole is closed with simple suture of the fascia
Study: NCT04208243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative Arts Therapy
Description: The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis.
Study: NCT02321306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Description: LUM001 administered orally once each day.
Study: NCT03721016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study: NCT02676115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medipore Tape
Description: * One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken.
Study: NCT00113087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo
Study: NCT02387931

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Nature Made Vitamin D 2000IU, 1 softgel taken daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
Study: NCT03721016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Study: NCT00009984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study: NCT02387931

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, 2 taken daily